Yong Ju Lee

Yong Ju Lee

Auto-generated profile, based on publicly available information

Yong Ju Lee

Department of Pediatrics, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PDPneumonia and Respiratory Disease Study Group of Korean Academy of Pediatric Allergy and Respiratory Disease
Pneumonia and Respiratory Disease Study Group of Korean Academy of Pediatric Allergy and Respiratory Disease
ELEun Lee
Eun Lee
CKChul-Hong Kim
Chul-Hong Kim
YLYong Ju Lee
Yong Ju Lee
HKHyo-Bin Kim
Hyo-Bin Kim
HYHyeon-Jong Yang
Hyeon-Jong Yang
Background: Community–acquired pneumonia (CAP) is one of the leading worldwide causes of childhood morbidity and mortality. Its disease burden varies by age and etiology and is time dependent. We aimed to investigate the annual and seasonal patterns in etiologies of pediatric CAP requiring hospitalization. Methods: We conducted a retrospective study in 30,994 children (aged 0–18 years) with CAP between 2010 and 2015 at 23 nationwide hospitals in South Korea. Mycoplasma pneumoniae (MP) pneumonia was clinically classified as macrolide-sensitive MP, macrolide-less effective MP (MLEP), and macrolide-refractory MP (MRMP) based on fever duration after initiation of macrolide treatment, regardless of the results of in vitro macrolide sensitivity tests. Results: MP and respiratory syncytial virus (RSV) were the two most commonly identified pathogens of CAP. With the two epidemics of MP pneumonia (2011 and 2015), the rates of clinical MLEP and MRMP pneumonia showed increasing trends of 36.4% of the total MP pneumonia. In children < 2 years of age, RSV (34.0%) was the most common cause of CAP, followed by MP (9.4%); however, MP was the most common cause of CAP in children aged 2–18 years of age (45.3%). Systemic corticosteroid was most commonly administered for MP pneumonia. The rate of hospitalization in intensive care units was the highest for RSV pneumonia, and ventilator care was most commonly needed in cases of adenovirus pneumonia. Conclusions: The present study provides fundamental data to establish public health policies to decrease the disease burden due to CAP and improve pediatric health.

1 January 2018 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
DSDae Jin Song
Dae Jin Song
WSWoo Jung Song
Woo Jung Song
JKJae Woo Kwon
Jae Woo Kwon
GKGun Woo Kim
Gun Woo Kim
MKMi-Ae Kim
Mi-Ae Kim
DLDae Hyun Lim
Dae Hyun Lim
Song DJ, et al. Allergy Asthma Immunol Res. 2018 Nov;10(6):591-613. https://doi.org/10.4168/aair.2018.10.6.591

1 January 2016 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
SLSo-Yeon Lee
So-Yeon Lee
KAKangmo Ahn
Kangmo Ahn
JKJihyun Kim
Jihyun Kim
GJGwang Cheon Jang
Gwang Cheon Jang
TMTaek Ki Min
Taek Ki Min
AGAtopic Dermatitis Study Group
Atopic Dermatitis Study Group
Lee SY, et al. Allergy Asthma Immunol Res. 2016 Nov;8(6):535-540. https://doi.org/10.4168/aair.2016.8.6.535

1 January 2017 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
KJKyunguk Jeong
Kyunguk Jeong
JKJihyun Kim
Jihyun Kim
KAKangmo Ahn
Kangmo Ahn
SLSo-Yeon Lee
So-Yeon Lee
TMTaek Ki Min
Taek Ki Min
SLSooyoung Lee
Sooyoung Lee
Jeong K, et al. Allergy Asthma Immunol Res. 2017 Sep;9(5):423-430. https://doi.org/10.4168/aair.2017.9.5.423

8 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YCYun Jung Choi
Yun Jung Choi
ECEun Hee Chung
Eun Hee Chung
ELEun Lee
Eun Lee
CKChul-Hong Kim
Chul-Hong Kim
YLYong Ju Lee
Yong Ju Lee
DSDong In Suh
Dong In Suh
Mycoplasma pneumoniae is a major causative pathogen of community-acquired pneumonia in children, and the treatment of choice is macrolides. There is an increasing trend in reports of refractory clinical responses despite macrolide treatment due to the emergence of macrolide-resistant M. pneumoniae. Early discrimination of macrolide-refractory M. pneumoniae pneumonia (MrMP) from macrolide-sensitive M. pneumoniae pneumonia (MSMP) is vital; however, testing for macrolide susceptibility at the time of admission is not feasible. This study aimed to identify the characteristics of MrMP in Korean children, in comparison with those of MSMP. In this multicenter study, board-certified pediatric pulmonologists at 22 tertiary hospitals reviewed the medical records from 2010 to 2015 of 5294 children who were hospitalized with M. pneumoniae pneumonia and administered macrolides as the initial treatment. One-way analysis of variance and the Kruskal-Wallis test were used to compare differences between groups. Of 5294 patients (mean age, 5.6 years) included in this analysis, 240 (4.5%), 925 (17.5%), and 4129 (78.0%) had MrMP, macrolide-less effective M. pneumoniae pneumonia, and MSMP, respectively. Compared with the MSMP group, the MrMP group had a longer fever duration, overall (13.0 days) and after macrolide use (8.0 days). A higher proportion of MrMP patients had respiratory distress, pleural effusion, and lobar pneumonia. The mean aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and C-reactive protein levels were the highest in the MrMP group, along with higher incidences of extrapulmonary manifestations and atelectasis (during and post infection). Pre-existing conditions were present in 17.4% (n = 725/4159) of patients, with asthma being the most common (n = 334/4811, 6.9%). This study verified that MrMP patients show more severe initial radiographic findings and clinical courses than MSMP patients. MrMP should be promptly managed by agents other than macrolides.

18 December 2019 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
HKHwan Soo Kim
Hwan Soo Kim
ISIn Suk Sol
In Suk Sol
DLDonghe Li
Donghe Li
MCMiyoung Choi
Miyoung Choi
YCYun Jung Choi
Yun Jung Choi
HKHyun Hee Kim
Hyun Hee Kim
Background: Mycoplasma pneumoniae is one of the most common pathogens causing community acquired pneumonia in children. Although the rate of macrolide-refractory Mycoplasma pneumoniae (MRMP) has increased, systemic glucocorticoids as a treatment option has not been validated yet. The purpose of this study was to assess the efficacy of glucocorticoids add-on in the treatment of MRMP in children through systematic review and meta-analysis. Methods: Data sources A systematic literature search was conducted using ten electronic bibliographic databases including English, Korean, Chinese and Japanese languages, up to March 8, 2018. Study selection The study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist and selected randomized control trials which compared the efficacy of glucocorticoids add-on to macrolide in the treatment of MRMP in children. Data extraction Two independent reviewers extracted: primary outcomes as hospital days, fever duration, and change in C-reactive protein (CRP) and main analysis was performed through meta-analysis with random effects model. Results: Twenty-four unique randomized controlled trials met the inclusion criteria. The mean length of hospital stay in glucocorticoids treatment group was significantly shorter than that in conventional macrolide-treatment group (Weighted mean difference (WMD) = − 4.03 days). The mean length of fever duration was significantly shorter in the glucocorticoid treatment group in comparison with the conventional treatment group (WMD = -3.32 days). Level of CRP after treatment was significantly lower in the glucocorticoid treatment group than that in the conventional treatment group (WMD = -16.03). Sensitivity analysis and subgroup analysis showed no significant improvement in heterogeneity. As limitations of the study, most of the studies included were from a single country and we were unable to control for heterogeneity across interventions, lack of standardized measures, and different time points of assessments across studies. Conclusions: Glucocorticoid add-on treatment for MRMP can significantly shorten the duration of fever and hospital stay and decrease the level of CRP. These results should be confirmed by adequately powered studies in the future.